<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164659">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711697</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056552</org_study_id>
    <secondary_id>NCI-2012-01934</secondary_id>
    <nct_id>NCT01711697</nct_id>
  </id_info>
  <brief_title>Standard Radiation Therapy Combined With High Dose, Ablative Radiation in Patients With Advanced Lung Cancer That Cannot be Removed by Surgery</brief_title>
  <official_title>An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose of radiation therapy in treating patients with
      locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation
      therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as
      stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly
      to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been
      shown to provide excellent results when used in early stage lung cancer, but has not yet
      been applied to patients with more advanced disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To test the safety and tolerability of an alternative fractionation regimen in locally
      advanced non-small cell lung cancer (NSCLC), consisting of 44 Gy with concurrent
      chemotherapy followed by a stereotactic body radiation therapy (SBRT) boost to remaining
      parenchymal and nodal disease. The maximum tolerated dose of the SBRT boost will be
      determined.

      SECONDARY OBJECTIVES:

      I. To assess local control. II. To assess distant metastasis and patterns of failure. III.
      To assess overall survival at 1 and 2 years.

      OUTLINE: This is a dose-escalation study of radiation therapy and SBRT.

      Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for
      4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.

      After completion of study treatment, patients are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) defined to be the dose level that results in a probability equal to 0.33 that a dose limiting toxicity (DLT) will be manifest using Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v.4)</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicities associated with this regimen using CTCAE v.4</measure>
    <time_frame>Up to 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Crude rates of grade 3 and greater acute toxicities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late toxicities associated with this regimen using CTCAE v.4</measure>
    <time_frame>After 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Crude rates of grade 3 and greater late toxicities will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be calculated for the entire cohort using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be calculated for the entire cohort using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be assessed with standard follow-up imaging, and the percentages of in-field failures versus regional nodal failures calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be calculated for the entire cohort using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be calculated for the entire cohort using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be calculated for the entire cohort using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Stage IIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)</arm_group_label>
    <other_name>SBRT</other_name>
    <other_name>stereotactic radiation therapy</other_name>
    <other_name>stereotactic radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven NSCLC

          -  Unresectable disease

          -  Clinical stage T1-T4, N1-3, M0

          -  Karnofsky performance status (KPS) &gt;= 70

        Exclusion Criteria:

          -  Prior history of lung cancer

          -  Pregnancy

          -  Prior history of radiation to the chest
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Higgins</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin A. Higgins</last_name>
      <phone>404-727-5671</phone>
      <email>kristin.higgins@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin A. Higgins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>October 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kristin Higgins, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
